In January 2019, Gaobo Medical Group and Beijing University of Traditional Chinese Medicine announced that they would cooperate in the areas of diagnosing and treating various forms of cancer. The two parties will cooperate on training doctors in interdisciplinary approaches to medical treatment, as well as setting up joint research facilities and constructing research hospitals in China.
On July 15, 2017, BeiGene and Celgene announced a global strategic oncology collaboration to help with the development of cancer treatments. The two companies plan to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1 (PD-1) inhibitor, BGB-A317, for patients with solid tumor cancers.
On February 2, 2016, BeiGene, which focuses on the discovery and development of innovative cancer drugs, successfully listed on the New York Stock exchange. The listing was the first IPO of the year in the US, raising $158 million. The proceeds will be used to help fund the company’s next stage of clinical trials.